Atheroprotective role of vinpocetine: an old drug with new indication
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Vinpocetine (VPN) effectively manages endothelial dysfunction and atherosclerosis by reducing inflammation and oxidative stress. It inhibits key pathways like nuclear factor kappa B (NF-κB) and phosphodiesterase 1 (PDE1), promoting plaque stability.
Area Of Science
- Cardiovascular Research
- Pharmacology
Background
- Endothelial dysfunction is a primary driver of atherosclerosis and hypertension.
- Atherosclerosis involves cytokine generation, smooth muscle cell proliferation, and migration.
- Vinpocetine (VPN) is explored for treating cerebrovascular disorders and endothelial dysfunction.
Purpose Of The Study
- To elucidate the mechanistic role of vinpocetine (VPN) in inhibiting atherosclerosis.
- To clarify VPN's molecular mechanisms in managing endothelial dysfunction.
Main Methods
- This narrative review synthesizes existing research on VPN's effects.
- Mechanisms investigated include inhibition of phosphodiesterase 1 (PDE1) and nuclear factor kappa B (NF-κB).
- Analysis focuses on VPN's impact on inflammatory cytokines, oxidative stress, and atherosclerotic plaque stability.
Main Results
- VPN inhibits pro-inflammatory cytokine release via NF-κB-dependent pathways.
- VPN reduces monocyte adhesion and migration by downregulating inflammatory gene expression.
- VPN mitigates oxidative stress by inhibiting NF-κB and PDE1, and enhances atherosclerotic plaque stability.
Conclusions
- Vinpocetine demonstrates efficacy in managing endothelial dysfunction and atherosclerosis.
- VPN's anti-inflammatory and antioxidant properties, alongside plaque stabilization, are key therapeutic mechanisms.
- VPN represents a potential therapeutic agent for atherosclerosis by targeting key inflammatory and oxidative pathways.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...